Jay Peters1, Harjinder Singh2, Edward G Brooks3, Joseph Diaz4, Thirumalai R Kannan5, Jacqueline J Coalson6, Janet G Baseman5, Marianna Cagle5, Joel B Baseman7. 1. Department of Medicine, University of Texas Health Science Center at San Antonio, TX. Electronic address: peters@uthscsa.edu. 2. Department of Medicine, University of Texas Health Science Center at San Antonio, TX. 3. Department of Pediatrics, University of Texas Health Science Center at San Antonio, TX. 4. Asthma and Allergy Associates of South Texas, San Antonio, TX. 5. Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, TX. 6. Department of Pathology, University of Texas Health Science Center at San Antonio, TX. 7. Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, TX; Department of Epidemiology, University of Washington School of Public Health, Seattle, WA.
Abstract
BACKGROUND: The role of Mycoplasma pneumoniae (Mp) in the initiation and persistence of asthma remains elusive. Mp community-acquired respiratory distress syndrome toxin (CARDS Tx) is a unique virulence factor that induces an intense lymphocytic response and exacerbates asthma in animal models. We sought to determine the incidence of Mp infection and the presence of CARDS Tx in subjects with refractory asthma (RA). METHODS: We conducted a prospective observational study in 64 subjects with RA. Respiratory secretions (sputum, nasal lavage, and throat swab) and blood were analyzed for the presence of CARDS Tx and P1 adhesin (P1) DNA by polymerase chain reaction (PCR), and CARDS Tx by antigen capture. Serum IgM and IgG antibodies to CARDS Tx were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: Thirty-three of 64 subjects (52%) tested positive for Mp: 29 of 33 by CARDS Tx vs 10 of 33 by P1 assays. Ten subjects followed longitudinally for up to 633 days tested persistently positive for Mp. There were no significant differences in Mp-specific IgG responses between Mp-positive and Mp-negative groups. Eight of 10 subjects who tested persistently positive failed to mount a substantial IgG response to CARDS Tx, and up to 8 weeks of clarithromycin failed to eradicate Mp in five subjects. CONCLUSIONS: Subjects with RA may be chronically infected with Mp. PCR for CARDS Tx appears to be the most sensitive method of identifying Mp infection. Despite the persistence of Mp in subjects with RA, some subjects failed to mount an IgG response, and macrolide therapy was insufficient to eradicate Mp.
BACKGROUND: The role of Mycoplasma pneumoniae (Mp) in the initiation and persistence of asthma remains elusive. Mp community-acquired respiratory distress syndrome toxin (CARDS Tx) is a unique virulence factor that induces an intense lymphocytic response and exacerbates asthma in animal models. We sought to determine the incidence of Mp infection and the presence of CARDS Tx in subjects with refractory asthma (RA). METHODS: We conducted a prospective observational study in 64 subjects with RA. Respiratory secretions (sputum, nasal lavage, and throat swab) and blood were analyzed for the presence of CARDS Tx and P1 adhesin (P1) DNA by polymerase chain reaction (PCR), and CARDS Tx by antigen capture. Serum IgM and IgG antibodies to CARDS Tx were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: Thirty-three of 64 subjects (52%) tested positive for Mp: 29 of 33 by CARDS Tx vs 10 of 33 by P1 assays. Ten subjects followed longitudinally for up to 633 days tested persistently positive for Mp. There were no significant differences in Mp-specific IgG responses between Mp-positive and Mp-negative groups. Eight of 10 subjects who tested persistently positive failed to mount a substantial IgG response to CARDS Tx, and up to 8 weeks of clarithromycin failed to eradicate Mp in five subjects. CONCLUSIONS: Subjects with RA may be chronically infected with Mp. PCR for CARDS Tx appears to be the most sensitive method of identifying Mp infection. Despite the persistence of Mp in subjects with RA, some subjects failed to mount an IgG response, and macrolide therapy was insufficient to eradicate Mp.
Authors: T R Kannan; R D Hardy; J J Coalson; D C Cavuoti; J D Siegel; M Cagle; O Musatovova; C Herrera; J B Baseman Journal: Clin Infect Dis Date: 2011-11-03 Impact factor: 9.079
Authors: Pamela R Wood; Jordan C Kampschmidt; Peter H Dube; Marianna P Cagle; Paola Chaparro; Norma S Ketchum; Thirumalai R Kannan; Harjinder Singh; Jay I Peters; Joel B Baseman; Edward G Brooks Journal: Ann Allergy Asthma Immunol Date: 2017-06-19 Impact factor: 6.347
Authors: Jorge L Medina; Jacqueline J Coalson; Edward G Brooks; Vicki T Winter; Adriana Chaparro; Molly F R Principe; Thirumalai R Kannan; Joel B Baseman; Peter H Dube Journal: Am J Respir Cell Mol Biol Date: 2012-01-26 Impact factor: 6.914
Authors: Argentina Becker; T R Kannan; Alexander B Taylor; Olga N Pakhomova; Yanfeng Zhang; Sudha R Somarajan; Ahmad Galaleldeen; Stephen P Holloway; Joel B Baseman; P John Hart Journal: Proc Natl Acad Sci U S A Date: 2015-04-06 Impact factor: 11.205
Authors: Sowmya Balasubramanian; Lavanya Pandranki; Suzanna Maupin; Kumaraguruparan Ramasamy; Alexander B Taylor; Peter John Hart; Joel B Baseman; Thirumalai R Kannan Journal: Cell Microbiol Date: 2019-05-09 Impact factor: 3.715
Authors: Jesus A Segovia; Te-Hung Chang; Vicki T Winter; Jacqueline J Coalson; Marianna P Cagle; Lavanya Pandranki; Santanu Bose; Joel B Baseman; Thirumalai R Kannan Journal: Infect Immun Date: 2017-12-19 Impact factor: 3.441